BNP Paribas Financial Markets Takes Position in LAVA Therapeutics (NASDAQ:LVTX)

BNP Paribas Financial Markets bought a new stake in LAVA Therapeutics (NASDAQ:LVTX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 41,800 shares of the company’s stock, valued at approximately $40,000. BNP Paribas Financial Markets owned about 0.16% of LAVA Therapeutics at the end of the most recent quarter.

Analysts Set New Price Targets

Several research firms have recently commented on LVTX. JMP Securities reaffirmed a “market perform” rating on shares of LAVA Therapeutics in a research report on Thursday, May 15th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 target price on shares of LAVA Therapeutics in a research report on Monday, March 31st. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, LAVA Therapeutics currently has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Price Performance

Shares of NASDAQ:LVTX opened at $1.32 on Wednesday. The company has a market capitalization of $34.72 million, a P/E ratio of -1.28 and a beta of 0.46. LAVA Therapeutics has a 1 year low of $0.85 and a 1 year high of $2.52. The business’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.21.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.24. On average, sell-side analysts anticipate that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

LAVA Therapeutics Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.